Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia

Catherine J. Lee, Soyoung Kim, Heather R. Tecca, Stephanie Bo-Subait, Rachel Phelan, Ruta Brazauskas, David Buchbinder, Betty K. Hamilton, Minoo Battiwalla, Navneet S. Majhail, Hillard M. Lazarus, Peter J. Shaw, David I. Marks, Mark R. Litzow, Saurabh Chhabra, Yoshihiro Inamoto, Zachariah DeFilipp, Gerhard C. Hildebrandt, Richard F. Olsson, Kimberly A. KasowJane L. Liesveld, Seth J. Rotz, Sherif M. Badawy, Neel S. Bhatt, Jean A. Yared, Kristin M. Page, Martha L. Arellano, Michael Kent, Nosha Farhadfar, Sachiko Seo, Peiman Hematti, Cesar O. Freytes, Alicia Rovo, Siddhartha Ganguly, Sunita Nathan, Linda Burns, Bronwen E. Shaw, Lori S. Muffly

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

There ismarkedpaucityofdata regarding late effects inadolescentsandyoungadults (AYAs)who undergo myeloablative conditioning (MAC) allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML).We evaluated late effects and survival in 826 1-year diseasefree survivors of MAC HCT for AYA AML, with an additional focus on comparing late effects based upon MAC type (total body irradiation [TBI] vs high-dose chemotherapy only). The estimated 10-year cumulative incidence of subsequent neoplasms was 4% (95% confidence interval [CI], 2%-6%); 10-year cumulative incidence of nonmalignant late effects included gonadal dysfunction (10%; 95% CI, 8%-13%), cataracts (10%; 95% CI, 7%-13%), avascular necrosis (8%; 95% CI, 5%-10%), diabetes mellitus (5%; 95% CI, 3%-7%), and hypothyroidism (3%; 95% CI, 2%-5%). Receipt of TBIwas independently associatedwith a higher risk of cataracts only (hazard ratio [HR], 4.98; P <.0001) whereas chronic graft-versus-host disease (cGVHD) was associated with an increased risk of cataracts (HR, 3.22; P 5 =0006), avascular necrosis (HR, 2.49; P 5 .006), and diabetes mellitus (HR, 3.36; P 5 =03). Estimated 10-year overall survival and leukemia-free survival were 73% and 70%, respectively, and did not differ on the basis of conditioning type. In conclusion, late effects among survivors of MAC HCT for AYA AML are frequent and are more closely linked to cGVHD than type of conditioning.

Original languageEnglish (US)
Pages (from-to)983-992
Number of pages10
JournalBlood Advances
Volume4
Issue number6
DOIs
StatePublished - Mar 24 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this

    Lee, C. J., Kim, S., Tecca, H. R., Bo-Subait, S., Phelan, R., Brazauskas, R., Buchbinder, D., Hamilton, B. K., Battiwalla, M., Majhail, N. S., Lazarus, H. M., Shaw, P. J., Marks, D. I., Litzow, M. R., Chhabra, S., Inamoto, Y., DeFilipp, Z., Hildebrandt, G. C., Olsson, R. F., ... Muffly, L. S. (2020). Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Advances, 4(6), 983-992. https://doi.org/10.1182/bloodadvances.2019001126